Hemophilia A - Pipeline Review, H2 2016

Date: November 23, 2016
Pages: 159
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H909533E405EN
Leaflet:

Download PDF Leaflet

Hemophilia A - Pipeline Review, H2 2016
Hemophilia A - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia A – Pipeline Review, H2 2016, provides an overview of the Hemophilia A (Hematological Disorders) pipeline landscape.

Hemophilia A is an X-linked, recessive disorder caused by deficiency of functional plasma clotting factor VIII (FVIII), which may be inherited or arise from spontaneous mutation. Depending on the level of FVIII activity, patients with hemophilia may present with easy bruising, inadequate clotting of traumatic injury or in the case of severe hemophilia spontaneous hemorrhage. Symptoms may include bleeding into joints, with associated pain and swelling, blood in the urine or stool, bruising, gastrointestinal tract and urinary tract hemorrhage, nosebleeds, prolonged bleeding from cuts, tooth extraction, and surgery and spontaneous bleeding.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hemophilia A – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hemophilia A (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemophilia A (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia A and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 8, 4, 4, 21, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.Hemophilia A.

Hemophilia A (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia A (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hemophilia A (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hemophilia A (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hemophilia A (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia A (Hematological Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hemophilia A (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hemophilia A (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Hemophilia A Overview
Therapeutics Development
Pipeline Products for Hemophilia A - Overview
Pipeline Products for Hemophilia A - Comparative Analysis
Hemophilia A - Therapeutics under Development by Companies
Hemophilia A - Therapeutics under Investigation by Universities/Institutes
Hemophilia A - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Hemophilia A - Products under Development by Companies
Hemophilia A - Products under Investigation by Universities/Institutes
Hemophilia A - Companies Involved in Therapeutics Development
Alnylam Pharmaceuticals Inc
Amarna Therapeutics BV
Apitope International NV
Bayer AG
Biogen Inc
BioMarin Pharmaceutical Inc
Catalyst Biosciences Inc
Chugai Pharmaceutical Co Ltd
CSL Ltd
DBV Technologies SA
Dimension Therapeutics Inc
Emergent BioSolutions Inc
EpiVax Inc
Expression Therapeutics LLC
Green Cross Corp
Idogen AB
Lentigen Technology Inc
mAbxience SA
Novo Nordisk A/S
Octapharma AG
OPKO Biologics Ltd
Pfizer Inc
Pharming Group NV
rEVO Biologics Inc
Sangamo BioSciences Inc
Shire Plc
SK Chemicals Co Ltd
Spark Therapeutics Inc
UniQure NV
XL-protein GmbH
Hemophilia A - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
antihemophilic factor - Drug Profile
antihemophilic factor (human) - Drug Profile
antihemophilic factor (recombinant) - Drug Profile
antihemophilic factor (recombinant) - Drug Profile
antihemophilic factor (recombinant) - Drug Profile
antihemophilic factor (recombinant) - Drug Profile
antihemophilic factor (recombinant) - Drug Profile
antihemophilic factor (recombinant) - Drug Profile
antihemophilic factor (recombinant) biosimilar - Drug Profile
antihemophilic factor (recombinant) biosimilar - Drug Profile
antihemophilic factor (recombinant), pegylated - Drug Profile
antihemophilic factor (recombinant), single chain - Drug Profile
ATXF-8117 - Drug Profile
BAX-888 - Drug Profile
BAY-1093884 - Drug Profile
BMN-270 - Drug Profile
Cell Therapy to Target Coagulation Factor VIII for Hemophilia A - Drug Profile
coagulation factor VIIa (recombinant) - Drug Profile
coagulation factor VIII (human) - Drug Profile
concizumab - Drug Profile
CSL-689 - Drug Profile
damoctocog alfa pegol - Drug Profile
Deimmunized FVIII - Drug Profile
DTX-201 - Drug Profile
emicizumab - Drug Profile
ET-3 - Drug Profile
fitusiran - Drug Profile
Gene Therapy for Hematological Disorders - Drug Profile
Gene Therapy for Hemophilia A - Drug Profile
Gene Therapy to Activate Factor VIII for Hemophilia A - Drug Profile
IN-3012 - Drug Profile
Kovaltry - Drug Profile
LG-889 - Drug Profile
LR-769 - Drug Profile
marzeptacog alfa - Drug Profile
MG-1113A - Drug Profile
MOD-5014 - Drug Profile
PBB-8-IN - Drug Profile
PF-06741086 - Drug Profile
Recombinant Factor VIII Replacement for Hemophilia A - Drug Profile
Recombinant Factor VIII Replacement for Hemophilia A - Drug Profile
Recombinant Protein for Hemophilia A - Drug Profile
Recombinant Proteins for Hemophilia A - Drug Profile
SB-525 - Drug Profile
SB-FVIII - Drug Profile
SHP-656 - Drug Profile
SPK-8011 - Drug Profile
SVF-VIIa - Drug Profile
Hemophilia A - Dormant Projects
Hemophilia A - Discontinued Products
Hemophilia A - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 155

LIST OF TABLES

Number of Products under Development for Hemophilia A, H2 2016
Number of Products under Development for Hemophilia A - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2016
Hemophilia A - Pipeline by Alnylam Pharmaceuticals Inc, H2 2016
Hemophilia A - Pipeline by Amarna Therapeutics BV, H2 2016
Hemophilia A - Pipeline by Apitope International NV, H2 2016
Hemophilia A - Pipeline by Bayer AG, H2 2016
Hemophilia A - Pipeline by Biogen Inc, H2 2016
Hemophilia A - Pipeline by BioMarin Pharmaceutical Inc, H2 2016
Hemophilia A - Pipeline by Catalyst Biosciences Inc, H2 2016
Hemophilia A - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016
Hemophilia A - Pipeline by CSL Ltd, H2 2016
Hemophilia A - Pipeline by DBV Technologies SA, H2 2016
Hemophilia A - Pipeline by Dimension Therapeutics Inc, H2 2016
Hemophilia A - Pipeline by Emergent BioSolutions Inc, H2 2016
Hemophilia A - Pipeline by EpiVax Inc, H2 2016
Hemophilia A - Pipeline by Expression Therapeutics LLC, H2 2016
Hemophilia A - Pipeline by Green Cross Corp, H2 2016
Hemophilia A - Pipeline by Idogen AB, H2 2016
Hemophilia A - Pipeline by Lentigen Technology Inc, H2 2016
Hemophilia A - Pipeline by mAbxience SA, H2 2016
Hemophilia A - Pipeline by Novo Nordisk A/S, H2 2016
Hemophilia A - Pipeline by Octapharma AG, H2 2016
Hemophilia A - Pipeline by OPKO Biologics Ltd, H2 2016
Hemophilia A - Pipeline by Pfizer Inc, H2 2016
Hemophilia A - Pipeline by Pharming Group NV, H2 2016
Hemophilia A - Pipeline by rEVO Biologics Inc, H2 2016
Hemophilia A - Pipeline by Sangamo BioSciences Inc, H2 2016
Hemophilia A - Pipeline by Shire Plc, H2 2016
Hemophilia A - Pipeline by SK Chemicals Co Ltd, H2 2016
Hemophilia A - Pipeline by Spark Therapeutics Inc, H2 2016
Hemophilia A - Pipeline by UniQure NV, H2 2016
Hemophilia A - Pipeline by XL-protein GmbH, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Actions H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Hemophilia A - Dormant Projects, H2 2016
Hemophilia A - Dormant Projects (Contd..1), H2 2016
Hemophilia A - Discontinued Products, H2 2016 143

LIST OF FIGURES

Number of Products under Development for Hemophilia A, H2 2016
Number of Products under Development for Hemophilia A - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Hemophilia B - Pipeline Review, H2 2016 US$ 2,000.00 Sep, 2016 · 112 pages

Ask Your Question

Hemophilia A - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: